Results 201 to 210 of about 12,926,306 (256)

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies. [PDF]

ESMO Open
Ekström-Rydén V, Carneiro A, Yachnin J, Staal Rohrberg K, Enell Smith K, Ellmark P, Løvendahl Eefsen R, Ullenhag GJ.   +7 more
europepmc   +1 more source

Cross‐Cancer Profiling of CDH1 Reveals Context‐Dependent EMT Decoupling, Immune Heterogeneity, and Prognostic Variability in Epithelial Cancers

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Cadherin 1 (CDH1) encodes E‐cadherin, a key epithelial adhesion molecule traditionally associated with tumor suppression and epithelial–mesenchymal transition (EMT). However, its roles across cancers remain incompletely understood, particularly within multilayer regulatory contexts involving genomic, epigenetic, transcriptional, and immune ...
Md. Abdur Rahman, Sm Faysal Bellah, Md. Mustafizur Rahman   +2 more
wiley   +1 more source

Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis. [PDF]

JNCI Cancer Spectr
Fujiwara Y, Okamura Y, Ramesh M, Tehrani YF, Aburaki R, Takahashi T, Ahluwalia MS, Mukherjee S.   +7 more
europepmc   +1 more source

Clinical Impact of CTLA4 and LAG3 Single‐Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T‐Cell Therapy

Hematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy targeting B‐cell maturation antigen (BCMA) is a highly effective treatment option for patients with relapsed refractory multiple myeloma (RRMM). However, reliable biomarkers predicting long‐term treatment response remain elusive. Germline single‐nucleotide polymorphisms (SNPs) in immune checkpoint
Elisa Suter, Martina Bertschinger, Inna Shaforostova, Marie‐Noelle Kronig, Henning Nilius, Ulrike Bacher, Katja Seipel, Thomas Pabst   +7 more
wiley   +1 more source

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, Volume 159, Issue 9, Page 2262-2277, 1 November 2026.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao   +4 more
wiley   +1 more source

Mechanistic drivers of PD-L1/CTLA-4 checkpoint inhibitor-associated immune toxicity and systemic organ injury. [PDF]

Front Oncol
Chen J, Zhang L, Gao M, Min S.
europepmc   +1 more source

High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy

International Journal of Cancer, Volume 159, Issue 9, Page 2314-2327, 1 November 2026.
ABSTRACT Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with an immunosuppressive tumor microenvironment, and current immunotherapy provides limited benefit. This highlights the need to identify microenvironmental features enabling effective immune responses.
Jiatian Fang, Zilian Wang, Hui Wang, Jianxin Xue, Kai Kang   +4 more
wiley   +1 more source

Role of CTLA-4 blockade and dacarbazine therapy following anti-PD-1 resistance in melanoma. [PDF]

Discov Oncol
Urbonas V, Dulskas A.
europepmc   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Low-Dose Interleukin-2 Enhances Activated Suppressor Regulatory T Cells and CTLA-4 and HLA-DR Expression in Chronic Chikungunya Arthritis. [PDF]

Pathogens
Tritsch SR, Mejia JF, Mendoza-Torres E, Sucerquia A, Adem A, Alzate-Alvarez JD, Agarwal R, Weiskopf D, Acosta E, Osorio-Llanes E, González AO, Pallares AP, Encinales MC, Paez VC, Contreras MJV, Alvarez MJS, Otero NS, Bañol DG, Kuang LT, Maestre LS, Rueda BM, Badel C, Simon GL, Firestein GS, Encinales L, Mores C, Cadena A, Chang AY.   +27 more
europepmc   +1 more source